ClinicalTrials.Veeva

Menu
P

Pusan National University Hospital | Rheumatology

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Risankizumab
RO7200220
Lenalidomide
Azacitidine
Vamikibart
Mavacamten
Upadacitinib
Dupilumab
Ruxolitinib

Parent organization

This site is a part of Pusan National University Hospital

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

7 of 10 total trials

A Study of Mavacamten in Non-Obstructive Hypertrophic Cardiomyopathy (ODYSSEY-HCM)

The purpose of this study is to evaluate the safety, tolerability, and efficacy of mavacamten compared with placebo in participants with symptomatic...

Active, not recruiting
Cardiomyopathy, Hypertrophic
Drug: Mavacamten
Other: Placebo

This study will be conducted in two parts. Part 1 will be the Dose Confirmation portion to determine recommended Phase 3 dose (RPTD) of venetoclax in...

Active, not recruiting
Acute Myeloid Leukemia (AML)
Drug: Venetoclax
Drug: Azacitidine

The study consists of 4 sub-studies, as follows:* Sub-study 1 (Randomized, double-blind, placebo controlled study) to evaluate the efficacy and safet...

Active, not recruiting
Crohn's Disease
Drug: Placebo for Risankizumab IV
Drug: Risankizumab SC

The purpose of this study is to evaluate safety and efficacy of risankizumab in participants with ulcerative colitis (UC) in participants who respond...

Active, not recruiting
Ulcerative Colitis (UC)
Drug: placebo for risankizumab
Drug: risankizumab

Study BP43445 is a phase II, multicenter, randomized, double-masked, active comparator-controlled study to investigate the efficacy, safety, tolerabi...

Active, not recruiting
Diabetic Macular Edema
Drug: Ranibizumab
Other: Sham Procedure

Myelofibrosis (MF) is a rare blood cancer, notable for scarring of the bone marrow (the spongy tissue inside bones) and the spleen becoming larger. T...

Active, not recruiting
Myelofibrosis (MF)
Drug: Best Available Therapy (BAT)
Drug: Ruxolitinib

Follicular Lymphoma (FL) is the second most common B-cell cancer and the most common type of cancer of lymphocytes. Unfortunately, this disease is in...

Enrolling
Follicular Lymphoma (FL)
Drug: Lenalidomide
Drug: Epcoritamab

Trial sponsors

AbbVie logo
Bristol-Myers Squibb (BMS) logo
Genmab logo
Roche logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems